Invex TherapeuticsASX:IXC 37 Market Cap is A$8.27 Mil as of Jun. 25, 2026. GuruFocus rates ASX:IXC with a GF Score™ of 37/100. The stock has 1 warning sign investors should review. Among 1,431 Biotechnology companies, Invex Therapeutics ranks worse than 89.73% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Invex Therapeutics's share price for the quarter that ended in Dec. 2025 was A$0.12. Invex Therapeutics's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 75.15 Mil. Therefore, Invex Therapeutics's market cap for the quarter that ended in Dec. 2025 was A$9.02 Mil.
Invex Therapeutics's quarterly market cap
increased
from Dec. 2024 (A$4.96 Mil) to Jun. 2025 (A$6.69 Mil) and
increased
from Jun. 2025 (A$6.69 Mil) to Dec. 2025 (A$9.02 Mil).
Invex Therapeutics's annual market cap
declined
from Jun. 2023 (A$15.03 Mil) to Jun. 2024 (A$4.51 Mil) but then
increased
from Jun. 2024 (A$4.51 Mil) to Jun. 2025 (A$6.69 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Invex Therapeutics's Enterprise Value for Today is A$3.67 Mil.
Invex Therapeutics (ASX:IXC) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Invex Therapeutics Market Cap Related Terms
Invex Therapeutics Market Cap Historical Data
* Premium members only.
The historical data trend for Invex Therapeutics's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IXC vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Invex Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invex Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Invex Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Invex Therapeutics's Market Cap for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invex Therapeutics (ASX:IXC) has a Market Cap of A$8.27 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Invex Therapeutics and its competitors. According to the industry distribution chart, Invex Therapeutics ranks #1284 out of 1431 companies in the Biotechnology industry, placing it in the top 89.7%.
Is Invex Therapeutics' Market Cap too high?
Invex Therapeutics' current Market Cap is A$8.27 Mil. Based on the distribution chart, Invex Therapeutics ranks #1284 out of 1431 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Invex Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Invex Therapeutics ranks #1284 out of 1431 companies for Market Cap. This places Invex Therapeutics in the lower half of its industry. The industry median Market Cap is 117.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Invex Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Invex Therapeutics's current Market Cap is A$8.27 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Market Cap of A$8.27 Mil. The current Market Cap is A$8.27 Mil. Invex Therapeutics' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Market Cap is A$8.27 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
37GF Score
Get the complete analysis for ASX:IXC
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IXC has been successfully added to your 
